Junkins-Hopkins JM - Search Results

1

Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.

Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Shapiro M, et al. J Am Acad Dermatol. 2002 Dec;47(6):956-61. doi: 10.1067/mjd.2002.124816. J Am Acad Dermatol. 2002. PMID: 12451388 No abstract available.

2

High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH. Richardson SK, et al. Clin Lymphoma Myeloma. 2006 Nov;7(3):226-32. doi: 10.3816/CLM.2006.n.063. Clin Lymphoma Myeloma. 2006. PMID: 17229339 Clinical Trial.

3

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.

Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Gormley RH, et al. J Am Acad Dermatol. 2010 Feb;62(2):300-7. doi: 10.1016/j.jaad.2009.02.035. Epub 2009 Nov 26. J Am Acad Dermatol. 2010. PMID: 19944484 Review.

4

Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.

McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. McGinnis KS, et al. J Am Acad Dermatol. 2004 Mar;50(3):375-9. doi: 10.1016/j.jaad.2003.10.669. J Am Acad Dermatol. 2004. PMID: 14988678

5

Progressive epidermotropic CD8+/CD4- primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis.

Gelfand JM, Wasik MA, Vittorio C, Rook A, Junkins-Hopkins JM. Gelfand JM, et al. J Am Acad Dermatol. 2004 Aug;51(2):304-8. doi: 10.1016/s0190-9622(03)00065-3. J Am Acad Dermatol. 2004. PMID: 15280854

6

Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1.

Richardson S, Budgin JB, Junkins-Hopkins JM, Vittorio CC, Lee J, Miller WT Jr, Rook AH, Kim EJ. Richardson S, et al. Arch Dermatol. 2005 Mar;141(3):301-4. doi: 10.1001/archderm.141.3.301. Arch Dermatol. 2005. PMID: 15781670 No abstract available.

7

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review.

8

Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.

Introcaso CE, Micaily B, Richardson SK, Junkins-Hopkins JM, Yoon JS, Kim EJ, Vittorio CC, Rook AH. Introcaso CE, et al. J Am Acad Dermatol. 2008 Apr;58(4):592-5. doi: 10.1016/j.jaad.2007.12.016. Epub 2008 Feb 4. J Am Acad Dermatol. 2008. PMID: 18249469

9

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

10

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.

Suchin KR, Junkins-Hopkins JM, Rook AH. Suchin KR, et al. Arch Dermatol. 2002 Sep;138(9):1137-9. doi: 10.1001/archderm.138.9.1137. Arch Dermatol. 2002. PMID: 12224972 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters